Completed PHASE2 INTERVENTIONAL NCT00119431

Kinetics, Efficacy and Safety of C1-Esteraseremmer-N

Pharmacokinetics, Clinical Efficacy and Safety of C1 Inhibitor Concentrate (C1-Esteraseremmer-N) for the Treatment of Hereditary (and Acquired) Angioedema

Sponsor: Prothya Biosolutions

Conditions Angioneurotic Edema Hereditary Angioedema Type I

Interventions C1 inhibitor concentrate

Updated 7 times since 2017 Last updated: May 1, 2009 Started: Sep 30, 2005 Completion: Mar 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Angioneurotic Edema and Hereditary Angioedema Type I, this trial is completed. The trial is conducted by Prothya Biosolutions and has accumulated 7 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Jan 2022 [monthly]

Completed PHASE2
Jul 2019 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jul 2019 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Prothya Biosolutions

Data source: Prothya Biosolutions

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Amsterdam, Netherlands
• Rotterdam, Netherlands